Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease.

Eran ZittanA Hillary SteinhartPavel GoldsteinRaquel MilgromIan M GralnekMark S Silverberg

Published in: Clinical and translational gastroenterology (2021)

In individuals with Crohn's disease, higher adalimumab drug levels at week 4 (>13.9 μg/mL) were significantly associated with biological remission at week 24.

Keyphrases

ulcerative colitis
rheumatoid arthritis
disease activity
juvenile idiopathic arthritis
placebo controlled
adverse drug
clinical trial
drug induced
double blind